Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists

J Med Chem. 2007 Jan 25;50(2):272-82. doi: 10.1021/jm061094b.

Scott D Kuduk ¹, Christina N Di Marco, Ronald K Chang, Michael R Wood, Kathy M Schirripa, June J Kim, Jenny M C Wai, Robert M DiPardo, Kathy L Murphy, Richard W Ransom, C Meacham Harrell, Duane R Reiss, Marie A Holahan, Jacquelynn Cook, J Fred Hess, Nova Sain, Mark O Urban, Cuyue Tang, Thomayant Prueksaritanont, Douglas J Pettibone, Mark G Bock

Affiliations

Affiliation

1 Department of Medicinal Chemistry, Merck Research Laboratories, Sumneytown Pike, P.O. Box 4, West Point, Pennsylvania 19486, USA.

PMID: 17228869 DOI: 10.1021/jm061094b

Abstract

A series of biphenylaminocyclopropane carboxamide based bradykinin B1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.

Name
Email *

	Sorry, but the email address you supplied was invalid.